INTRODUCTION
Hepatitis-C (CHC) is a one of the biggest global chronic disease, affecting almost every geographical corner of the world. The global prevalence of "Hepatitis-C is 2.4%, affecting >200 million people worldwide". About half of these patients ultimately end with "cirrhosis and Hepatoma without treatment". 1, 2 Numbers of cases are decreasing in "developed world due to implementation of extensive screening measures before blood transfusion, surgical interventions, organs transplantation and over all allocation of health resources". But on the other hand, developing countries still face heavy problems due to "low literacy level, bad health care services, low budget and unregistered practices". That is why new cases are still coming into the old pool in heavy numbers. Although new cases are increasing, but at the same time "new treatment arms are coming into practice in the therapeutic armamentarium against Hepatitis-C". 3 This history starts from "conventional interferon, then peg-interferon and now to highly effective, Direct Acting Antiviral (DAAs), drugs like sofosbuvir and Daclatasvir etc". American association for the Study of Liver Disease (AASLD) 4, 5 and European Association for the Study of Liver (EASL) 6 recommend "Sofosbuvir and ribavirin for 24 weeks in the treatment of HCV genotype 3 infections in all patients with or without cirrhosis".
Along with viral factors and genotyping, "response to treatment in all these modalities is also affected by some human factors too". It does include sex, age and genetic factors like "IL-28B-CC or non-CC genotyping, officially called as (Interleukin-28B, "interferon, lambda3"). It is now clear, "that Hepatitis-B and Hepatitis-C is responsible for >75% of liver disease, including Cirrhosis and Hepatoma" and have substantial impact on morbidity, mortality and utilization of health budget. So it wisely needs aggressive treatment and addressing of all factors that can influence the success of treatment. It is documented and established in research, that "unfavorable non-CC (IL28B-rs12979860-non-CC) genotyping in human due to single nucleotide polymorphism (SNIPs) have bad impacts in treatment success for Chronic Hepatitis-C (CHC), treated with Pegylated-Interferon plus weight based ribavirin". But unlike Peg-Interferon, "the role of unfavorable non-CC (IL28B-rs12979860-non-CC) genotyping in treatment success with nucleotide analogue NS5B-HCV-RNA dependent RNA-polymerase inhibitor, Sofosbuvir, which is a new DAAs, is still debatable". Most of these studies are conducted internationally to evaluate the role of "unfavorable non-CC (IL28B-rs12979860-non-CC) genotyping in Genotype-1 infection. 7, 8 " Our community has "different genetic parameters and is mainly affected by Genotype-3a, which has different response to different treatment regimen, therefore it should be evaluated in our community". Moreover, this study will also fill the deficiency of available data and literature, "which is not sufficient to address this association in our community". Furthermore, unlike other factors like "viral genotyping, cirrhosis, age, gender, baseline viral load, the importance of unfavorable non-CC (IL28B-rs12979860-non-CC) genotyping will get clear as having no significant effects on antiviral therapy".
MATERIALS AND METHODS
The study was mainly conducted on patients, who visited different public and private tertiary care hospitals and consultant clinics in Peshawar District of Pakistan. The assumed duration of study was 6-months, starting from March 2016 to August 2016. Total 70-patients were selected, "having chronic Hepatitis C genotype 3a infections". All selected patients were distributed into two groups (1:1), 35 in each including "group-A as those having favorable CC (IL28B-rs12979860-CC) genotyping and group-B as those having unfavorable non-CC (IL28B-rs12979860-non-CC) genotyping". All patients with cirrhosis, Chronic Liver disease due to other causes and Concomitant Hepatitis-B or HIV infections and patients infected by other genotypes of Hepatitis-C were excluded from the study. To ensure good compliance and tolerability, patient with "advanced renal, cardiac diseases and cognitive dysfunctions were excluded from the study". All these patients were put on Sofosbuvir plus ribavirin for 6months. After the end of 24weeks treatment, HCV-RNA-PCR was done and was labeled as SVR12. The open labeled, prospective design was used in the study.
Data Collection
After ethical approval for the study from ethical committee of Hayat Abad Medical Complex Peshawar, "informed consent was obtained from the patients prior to their enrollment for the same study and treatment strategy". The demographic information of the subjects such as names, age, gender and data regarding HCVG3a and IL-28B were recorded according to the predefined inclusion/exclusion criteria. "Viral RNA was extracted and reverse transcribed to cDNA using Viral RNA extraction and cDNA synthesis kit (Qiagen, USA), respectively." HCV-RNA-PCR, genotyping and SVR12 were done with Qaigen-kit, using Rotorgen-6000 Molecular System, having Lower limit of quantification (LLOQ)<40IU/ml. IL-28B genotyping was done using genesig snpsig kit with special primer at the start of treatment.
Data Analysis
All data was entered in Microsoft Office Excel 2007, tabulated and analyzed by using SPSS statistical program. The data was expressed as mean percentage and presented in tabulated form. were male and 42.85% (n=30) were female, with mean age of 37±1.26 years. Age distribution "among 70-patients was analyzed as n=7 (10%) patients were in age group of 21-30 years, n=14 (20%) patients were in age group of 31-40 years, n=28 (40%) patients were in age group of 41-50 years, n=14 (20%) patients were in age group of 51-60 years and n=7 (10%) patients were above 60 years of age" as shown in Table-I. In all 35-patients in "group-A, n=21(60%) were male and n=14(40%) were female, while in group-B, n=19(54.28%) were male and n=16(45.72%) were female" as shown in Table- I (a).
RESULTS

Out
The status of "SVR12 among 70 patients was analyzed in both groups. Rate of SVR12 was 88.57% (n=31/35) in group-A, 91.42% (n=32/35) in group-B" as shown in Table-II. Status of "SVR12 in male and female was analyzed in both groups as 87.5% (n=35/40) male and 93.33% (n=28/30) female have achieved SVR12, as shown in Table- III". The overall response in both groups is also shown, which is 90%.
Status of male and female, who have not responded in group-A with favorable (IL28B-rs12979860-CC) genotyping was ¾ and ¼ respectively, in group-B with unfavorable (IL28B-rs12979860-non-CC) genotyping was 2/3 and 1/3, respectively. 
DISCUSSION
In Chronic Hepatitis-C, aggressive approach is needed while treating every patients suffering from this crippling disease. In last decade, "the paradigm shift of treatment from interferon based therapy to direct acting anti-viral therapy has totally changed the direction of research around the globe". At the same time it has also changed the approach to look for all factors affecting the treatment response. 9,10 Our population is mainly affected by "HCV-G3 infection, especially G3a, which is notoriously popular for causing cirrhosis". The new drug, like sofosbuvir in the therapeutic armamentarium against HCV which is recommended by "European Association for the Study of Liver (EASL) and American Association for the Study of Liver Diseases (AASLD)" has given a new hope both to the clinician and patients to be used safely in all cirrhotic and non-cirrhotic patients.
Unlike interferon, "the human interleukin and other inflammatory mediators have minimal or no role in treatment response to this drug, as it is not affecting the human immune system". In our study, the response rate in both group of patients with "favorable CC (IL28B-rs12979860-CC) genotyping and unfavorable non-CC (IL28B-rs12979860-non-CC) genotyping are almost same with a little better edge in group-B with unfavorable non-CC (IL28B-rs12979860-non-CC) genotyping". The overall response rate in this study are close to the finding of "VALENCE clinical trials by Gilead Sciences, which show 84% (210/250) SVR12, in all cases with HCVgenotype3 infection, treated with Sofosbuvir and ribavirin for 24weeks".
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In another clinical trial at the name of NEUTRINO by Gilead Sciences, "conducted on other genotypes of HCV, it has been confirmed that SVR12 rate is similarly high in both subject of IL28B genotyping, which is 94/95(99%) in IL28B-CC allele and 202/232(87%) with IL28B non-CC allele". 12 In another study by J.A holmes et.al, while evaluating the role of "IL-28B genotyping in response to different DAAs, it has been confirmed that IL-28B genotyping have no impacts on response to DAAs". They also found that, "even the impacts of IL-28B genotyping on Peginterferon can be reduced by adding one or two DAAs to triple or quadruple therapy along with Peg-interferon in the treatment of chronic Hepatitis-C. 13 Some other shared findings include "role of IL28B non-rs12979860-CC genotyping in new and treated cases, male sex, stage of cirrhosis and general built of the patient in treatment response to Sofosbuvir based regimen need serious consideration". However single genotype, straightforward new cases and small sample size are the main limitations of the present study.
Sofosbuvir is not only "effective but also safe, as some of the most common adverse effect observed in this study were, aches and pains, flue like symptoms and insomnia, but all were mild in nature and none of the patient discontinue the treatment".
And finally, it is now suggested and even accepted worldwide with many trials, "that all patients with HCV infection, who are candidates to be treated with Sofosbuvir based regimen should not be investigated unnecessarily for unfavorable non-CC (IL28B-rs12979860-non-CC) genotyping, as it has no role on treatment response with sofosbuvir in any patients with any Viral genotyping".
However, large trial is needed to address role of age, sex, initial viral load, status of the liver (i.e. Cirrhosis) and HCV sub-genotypes in response to Sofosbuvir in Pakistani population.
CONCLUSION "Sofosbuvir and Ribavirin based dual therapy is currently the most popular and effective treatment in all cases with Chronic Hepatitis-C genotype3a infections, and unfavorable non-CC (IL28B-rs12979860-non-CC) genotyping have no effect on treatment response' to this combination in Pakistani population. Further confirmation is suggested, "Both at national and international level on huge number of patients with HCVgenotype-3a infection". 
